We are a purpose-driven team, passionate about developing innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions for underserved mental health disorders, initially focusing on generalized anxiety disorder (GAD), adjustment disorder (AjD) and, major depressive disorder (MDD), including postpartum depression (PPD).

Leveraging our team’s extensive experience in psychedelics and neuroscience drug development, we are advancing luvesilocin, a patented, clinical-stage drug candidate designed as a safe, fast-acting, short duration therapy for patients with underserved mental health disorders.